#Japan IVIG for Myasthenia Gravis Market Report
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
Mobile US users spent an average of 115.8 minutes on Tumblr app monthly.
Text
Impact Analysis on COVID-19: Japan IVIG for Myasthenia Gravis Market Expected to Reach USD 29.7 Million, by 2024
According to a recent report published by KD Market Insights, titled, Japan IVIG for Myasthenia Gravis Market 2018: Market Size, Market Volume, Trends, Opportunity, Forecast 2018-2024, Japan intravenous immunoglobulin for myasthenia gravis market accounted for USD 19.4 Million in 2018 and is estimated to reach USD 29.7 Million by 2024. Moreover, it is anticipated to flourish at a CAGR of 7.5% during the forecast period, i.e. 2019-2024.
Japan intravenous immunoglobulin for myasthenia gravis market has been segmented on the basis of end users into hospital, clinics and home care. In the end user segment, hospital segment is expected to be the most attractive market in Japan intravenous immunoglobulin for myasthenia gravis market over the forecast period. Further, this segment is projected to open new avenues for the market players and to be the most lucrative market over the forecast period. Consumption of intravenous immunoglobulin for myasthenia gravis in hospital is expected to reach 238.2 KG by the end of 2024 from 169.6 KG in 2018. Apart from this, when compared with other segments, home care segment is anticipated to attain the highest CAGR over the upcoming years i.e. 2018-2024.
Request for Sample: https://www.kdmarketinsights.com/sample/5211
Launch of New & Improved Version of Drugs
Factor such as strong pipeline, increased focus on R&D, raising awareness, and adoption of novel therapies are driving the growth of Japan intravenous immunoglobulin market for myasthenia gravis. Various pharmaceutical firms are engaged in extensive research and development activities for efficient therapeutics for myasthenia gravis diseases. Furthermore, multiple clinical trials are being carried, which is expected to bring advanced therapeutics for the people.
Increasing Prevalence of Myasthenia Gravis
The rise in the prevalence of myasthenia gravis in Japan is envisioned to bolster the growth of the market during the forecast period. In Japan, the estimated number of patients with myasthenia gravis in 2006 was 15,100; giving a prevalence of 11.8 per 100 000 persons. Further, the number of patients and the prevalence rate has witnessed an increase in the past few years. This factor is expected to drive the growth of the market in the years ahead.
Competitive Landscape:
The report also covers detailed competitive analysis of major market players of Japan intravenous immunoglobulin for myasthenia gravis market, such as CSL Behring, Pfizer Inc., Grifols, Baxter, Takeda Pharmaceutical Company Limited and other major & niche players. Japan intravenous immunoglobulin for myasthenia gravis market is witnessing a wide range of industry activities such as acquisition, expansion, and partnership across the country. For instance, in January 2019, Takeda completed the acquisition of Shire, becoming a global and R&D-driven biopharmaceutical leader headquartered in Japan.
Market Segmentation Analysis:
By End User
- Hospital - Clinic - Homecare
Browse Full Report & TOC: https://www.kdmarketinsights.com/product/japan-intravenous-immunoglobulin-myasthenia-gravis-market
#Japan IVIG for Myasthenia Gravis Market#Japan IVIG for Myasthenia Gravis Market size#Japan IVIG for Myasthenia Gravis Market share#Japan IVIG for Myasthenia Gravis Market News#Japan IVIG for Myasthenia Gravis Market Trends#Japan IVIG for Myasthenia Gravis Market Research#Japan IVIG for Myasthenia Gravis Market Report
0 notes
Text
Intravenous Immunoglobulin (IVIg) Market expected to witness relatively significant growth in 2027
Intravenous Immunoglobulin (IVIg) Market Overview :
The intravenous immunoglobulin (IVIg) market is projected to grow by US$10,485.86 Million by 2027 rapidly at a CAGR of 6.30% throughout the forecast period. Developing healthcare infrastructure as well as increasing demand for alternative therapies drive the global intravenous immunoglobulin (IVIg) market. These key growth drivers have incredibly helped the intravenous immunoglobulin (IVIg) market and are estimated to boost the growth. Analysts studying the intravenous immunoglobulin (IVIg) market have also shared growth projections in the intravenous immunoglobulin (IVIg) market research report and have suggested intravenous immunoglobulin (IVIg) market-based companies to develop growth strategies. LAck of awareness about therapies as well as slow economic growth in developing countries are the challenges that companies across the intravenous immunoglobulin (IVIg) market could face. The details covered in the intravenous immunoglobulin (IVIg) market report cover all the aspects of the industry.
Get customized Sample with complete Toc, @ https://www.marketresearchfuture.com/sample_request/3137
Intravenous Immunoglobulin (IVIg) Market Segmentation :
The global intravenous immunoglobulin (IVIg) market has been segmented based on type and applications. On the basis of type, the market for intravenous immunoglobulin (IVIg) is segmented based on IgD, IgE, IgG, IgM, and IgA. Additionally, the market on the basis of applications, is segmented into Guillain-Barre syndrome, hypogammaglobulinemia, immunodeficiency diseases, ITP, Kawasaki disease, multifocal motor neuropathy, myasthenia gravis, primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), and others.
Factors like increasing R&D funding and rising healthcare expenditure propel the intravenous immunoglobulin (IVIg) market growth. The intravenous immunoglobulin (IVIg) market performance has also been studied. The intravenous immunoglobulin (IVIg) market report provides analysis of past and current trends. In addition to this, the intravenous immunoglobulin (IVIg) market report offers detailed analysis of type and applications segments. The market segmental analysis provided in the intravenous immunoglobulin (IVIg) market research report offers crucial details about the intravenous immunoglobulin (IVIg) market based on the data and forecasts till 2027.
Intravenous Immunoglobulin (IVIg) Market Regional Overview :
The intravenous immunoglobulin (IVIg) market report covers companies functional in the intravenous immunoglobulin (IVIg) market spread across regional markets of North America, Europe, Asia-Pacific (APAC), and the rest of the world. The regional analysis of the intravenous immunoglobulin (IVIg) market can be found in the market research report. The North American intravenous immunoglobulin (IVIg) market has several key players functioning in the United States, Canada, and Mexico. Europe has companies in the intravenous immunoglobulin (IVIg) market across Germany, France, Spain, Italy, and the United Kingdom. The intravenous immunoglobulin (IVIg) market of the Middle East, Africa, and other regions has also been studied by analysts. A detailed analysis of the intravenous immunoglobulin (IVIg) market across India, China, and Japan in the Asia-Pacific region is also available for further study.
Intravenous Immunoglobulin (IVIg) Market Competitive Landscape :
The intravenous immunoglobulin (IVIg) market is corroborated by developing healthcare infrastructure. The population growth as well as increasing demand of intravenous immunoglobulin (IVIg) market based solutions also accelerate the market growth. However, the intravenous immunoglobulin (IVIg) market can be affected due to low levels of awareness as well as lack of advanced infrastructure. The intravenous immunoglobulin (IVIg) market research report covers all such factors assisting companies in the intravenous immunoglobulin (IVIg) market to improve their plans and portfolio. The intravenous immunoglobulin (IVIg) market research report also provides company profiles of major businesses. The intravenous immunoglobulin (IVIg) market report highlights crucial details about organizations operating across North America, Europe, Asia-Pacific (APAC), and the rest of the world regional markets. The details available in the intravenous immunoglobulin (IVIg) market report cover company strategies, revenue, company size, and mergers and acquisitions in the intravenous immunoglobulin (IVIg) market. New entrants as well as established organizations can use the data from intravenous immunoglobulin (IVIg) market report to further plan their strategies.
Intravenous Immunoglobulin (IVIg) Industry News :
A research presented at the 2020 American Society of Hematology Virtual Symposium on the impact of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab (Darzalex) showed that hypogammaglobulinemia was pretty ubiquitous throughout daratumumab therapy, indicating a role for IVIG, particularly in patients with chronic infections.
Get Premium Research Report, Inclusive of COVID-19 Impact Analysis, Find more information @ https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137
#IntravenousImmunoglobulin(IVIg)Market#IntravenousImmunoglobulinMarketSize#IntravenousImmunoglobulin(IVIg)MarketForecast#IntravenousImmunoglobulin(IVIg)MarketStudy#IntravenousImmunoglobulin(IVIg)MarketTrends
1 note
·
View note
Text
Intravenous Immunoglobin (IVIG) Market Key Players, Competitive Landscape, Growth, Statistics, Revenue and Industry Analysis Report by 2027
The Global Intravenous Immunoglobin (IVIG) Market report gives a comprehensive overview of the Intravenous Immunoglobin (IVIG) market scenario to present accurate forecasts of the upcoming years with special focus on the competitive landscape, market segmentation, current and emerging trends, and strategic recommendations to help readers gain a robust footing in the market. The report also focuses on the comprehensive analysis of the competitive landscape along with descriptive company profiles, market share, product portfolio, financial standings, market reach, global position, and strategic business expansion plans.
The report is furnished with the latest market scenario pertaining to the COVID-19 pandemic and its after-effects on the Intravenous Immunoglobin (IVIG) industry and the key segments. The pandemic has disrupted the workflow of the industry and created financial difficulties. The report assesses the complete impact of the pandemic on the market and offers key insights into the market scenario along with trends and demands disruptions. The report also offers an outlook on the market scenario in the forecast timeline.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1442
Some of the players profiled in the report are Omrix Biopharmaceuticals Ltd., Hualan Biological Engineering Inc., Shanghai RAAS Blood Products Co. Ltd., Behring GmbH, Option Care Enterprises, Inc., BioScrip, Inc, ADMA Biologics, Inc., CSL Ltd., Baxter International Inc., Kedrion Biopharma Inc., Grifols S.A, LFB group, Octapharma AG, China Biologics Products, Inc., Biotest AG, and Takeda Pharmaceuticals have been profiled in the report.
The Global Intravenous Immunoglobin (IVIG) Market is segmented as follows:
Type Outlook (Revenue, USD Billion; 2017-2027)
IgG
IgA
IgM
IgE
IgD
Application Outlook (Revenue, USD Billion; 2017-2027)
Hypogammaglobulinemia
Immunodeficiency Diseases
Congenital AIDS
Chronic Inflammatory Demyelinating Polyneuropathy
Myasthenia Gravis
Multifocal Motor Neuropathy
Specific Antibody Deficiency
Guillain-Barre syndrome
Kawasaki Diseases
Others
End-Use Outlook (Revenue, USD Billion; 2017-2027)
Hospitals
Clinics
Homecare
Others
Market Segmentation by Regions:
North America (U.S., Canada)
Europe (U.K., Italy, Germany, France, Rest of EU)
Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1442
Key Point Summary of the Report:
The global Intravenous Immunoglobin (IVIG) market research report is an investigative study offering key insights into the latest growth trends, developments, technological and product advancements, and the research and development scenario. The report also covers the market aspects that directly influence the growth of the market. These features include strategies undertaken by the prominent players, their expansion tactics, and the product portfolios of the companies, and micro and macro-economic factors.
The study also analyses the crucial market aspects, including R&D, product launches and brand promotions, mergers and acquisitions, collaborations, joint ventures, and the growth pattern on both regional and global levels. The report offers an in-depth evaluation of factors such as cost, capacity, rates of production and consumption, gross revenue, profit margin, demand and supply ratio, import/export, market share, market size, and market trends.
The Global Intravenous Immunoglobin (IVIG) Market includes relevant and verified information relating to the overall market, key players, and their market position and financial standing. The report utilizes advanced analytical tools such as SWOT analysis, Porter’s Five Forces Analysis, investment return analysis, and feasibility analysis to offer a comprehensive view of the market position of the major players of the industry.
To know more about the report, visit @ https://www.reportsanddata.com/report-detail/intravenous-immunoglobulin-market
To summarize everything stated above, the report offers key insights into the Intravenous Immunoglobin (IVIG) market to allow the reader to gain a complete understanding of the Global Intravenous Immunoglobin (IVIG) Market through accurate estimations, a panoramic view of the market scenario, competitive landscape, factors influencing the growth of the market, driving factors, restraints, regulatory framework, growth prospects and opportunities, and factors propelling the market forward. The research study offers an in-depth view of the industry to offer a competitive edge to the reader and help them in formulating beneficial investment plans. The report provides a comprehensive overview of the market with facts relating to the past, present, and future of the Global Intravenous Immunoglobin (IVIG) Market.
Thank you for reading the report. The report can be customized as per the requirements of the clients. For further information or queries about customization options, please reach out to us, and we will offer you the report best suited for your needs.
0 notes
Text
Intravenous Immunoglobulin (IVIG) Market Sales Influenced by Improved Technological Arrangement during 2020-2025
The Global Intravenous Immunoglobulin (IVIG) Market 2020 report delivers a fundamental overview of the industry, including definitions, segmentation, applications and industry chain structure analysis. The intravenous immunoglobulin (IVIG) market report provides competitive landscape analysis, major trends, and key regional development status. It also offers a competitive framework for major revenue-contributing firms covering company market shares with comprehensive profiles. The report provides a key overview of the market status of intravenous immunoglobulin (IVIG) market manufacturers with market size, share, growth, market expansion, and technological innovations, as well as the industry cost structure.
It provides the impact and recovery of Covid-19 pandemic on the intravenous immunoglobulin (IVIG) Market. Relevant statistical data is also provided in the report to recognize the challenges caused by the outbreak of Covid-19 and strategies to cope up with the current scenario.
CLICK HERE FOR FREE SAMPLE REPORT: https://www.factomarketinsights.com/sample/228
The Following are the Key Features of Intravenous Immunoglobulin (IVIG) Market Report:
Market Overview, Industry Development, Market Maturity, PESTLE Analysis, Value Chain Analysis
Growth Drivers and Barriers, Market Trends & Market Opportunities
Porter’s Five Forces Analysis & Trade Analysis
Market Forecast Analysis for 2020-2025
Market Segments by Geographies and Countries
Market Segment Trend and Forecast
Market Analysis and Recommendations
Price Analysis
Key Market Driving Factors
Intravenous Immunoglobulin (IVIG) market Company Analysis: Company Market Share & Market Positioning, Company Profiling, Recent Industry Developments etc.
Market Segmentation:
The segmentation of intravenous immunoglobulin (IVIG) market is as follows By Application, By Type. Both developed and developing regions are extensively studied in the report.
By Application
Hypogammaglobulinemia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Primary Immunodeficiency Disease Myasthenia Gravis Multifocal Motor Neuropathy Idiopathic Thrombocytopenic Purpura (ITP) Inflammatory Myopathies Specific Antibody Deficiency Guillain–Barre Syndrome Others
By Type
IgG IgA IgM IgE IgD
By Geography
The regional segmentation of the market covers following regions: North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East & Africa (GCC, North Africa, South Africa, and Rest of Middle East & Africa).
Fundamental Coverage of the Intravenous Immunoglobulin (IVIG) Market:
Covid-19 impact and strategies to recover.
Valuable information about the intravenous immunoglobulin (IVIG) Market
Identification of growth in various segments and sub segments of the studied market.
Strategic ideas for investment opportunities
Key statistical data along with products, price analysis, applications, levels of production and consumption, supply and demand.
Emerging developments in the existing market segment and research to help investors devise new business strategies
Accelerates decision-making by drivers and constraints
Competitive Analysis
The key players of the market are listed in this section of the study. It helps to understand the tactics and alliances that players concentrate on fighting market rivalry. An essential microscopic look at the market is given in the detailed study. The major players operating in the intravenous immunoglobulin (IVIG) market are:
Baxter international Inc. CSL Ltd. Grifols, S.A. Octapharma AG Kedrion Biopharma Inc. LFB Group Biotest AG China Biologics Products, Inc. Takeda Pharmaceuticals Bayer AG
CLICK HERE FOR INQUIRY BEFORE BUYING THIS REPORT: https://www.factomarketinsights.com/enquiry/228
About Us:
Facto Market Insights is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on industries, companies, products, and trends.
Our in-house research experts have a wealth of knowledge in their respective domains. With Facto Market Research, you always have the choice of getting customized report free of cost (up to 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.
Our clients list includes various Fortune 500 companies and leading advisory firms.
Contact Us:
Facto Market Insights
90 State Street, Albany,
New York, USA 12207
+1 (518) 250-1215
Email:[email protected]
Website: www.factomarketinsights.com
0 notes
Text
Intravenous Immunoglobulin (IVIG) Market Size, Share, Trends And Industry Growth Analysis, Forecast To 2027
Intravenous Immunoglobulin (IVIG) Market Overview
Intravenous Immunoglobulin (IVIg), a compound comprising of immune proteins (globulins) is administered into the bloodstream to treat patients with inefficient or damaged immune systems. IVIg provides the required antibodies by the human body to fight out the immune deficiency, and the ensuing infectious attacks.
Immunodeficiency disorder could be a hereditary issue (Primary disorders), or caused due to the exposure to infections, mainly through bodily fluids, along with the cancer drugs and chemotherapy, aging is one of the key risk factors too that could put someone at higher risk of a damaged immune system.
People nowadays are increasingly adopting heady & unhealthy lifestyles which mirror the prevalence of damaged immune system. Factors such as immense stress, lack of good quality sleep, inadequate & improper diet and sedentary lifestyle are fuelling the prevalence of immunodeficiency disorder and therefore, predominantly driving the growth of the market.
Fill Out Details To Receive FREE Sample Here: https://www.marketresearchfuture.com/sample_request/3137
The augmenting demand for alternate immunoglobulin replacement therapies, increasing R&D funding, rapidly developing healthcare infrastructure and increasing healthcare expenditures are major driving forces for the market growth. Technological advancements transpired in medical science, are fostering the growth of the market exponentially, bringing up new treatment procedures, & medications in the field of IVIg.
Additionally, factors such as growing population and geriatric populace worldwide are fostering market growth. Rapidly developing economy worldwide is providing impetus to the market growth, enabling access to the quality life & improved healthcare. Substantial investments made in the development of IVIg, by the key market players are paying off well, driving the growth of the market.
On the flip side, factors such as low awareness among people about the availability of treatment, the high cost of IVIg management along with the skepticism towards the advancement & efficacies of these treatments among the patients are likely to impede the growth of the Intravenous Immunoglobulin market.
Intravenous Immunoglobulin (IVIg) Market Major Players:
Key players leading the global IVIg market include Baxter (US), BDI Pharma (US), Abeona Therapeutics (US), China Biologic Products, Inc. (China), Grifols Inc. (Spain), Biotest AG. (Germany), CSL Behring (US), Octapharma (Switzerland), Kedrion S.p.A (US), and Shire (Republic of Ireland) among others.
Intravenous Immunoglobulin (IVIg) Industry, Innovation & Related News
March 28, 2019 --- CSL Behring (the US), a leading global biotherapeutics and biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products announced the receiving of an approval from Japan's Ministry of Health, Labour and Welfare has for two of its immunoglobulin therapies - named Hizentra and Privigen for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
Out of these, Hizentra which was previously approved for the treatment of primary immunodeficiency (PI) is now Japan's first and only subcutaneous immunoglobulin (SCIG) treatment approved for maintenance therapy to treat CIDP. Privigen, an intravenous immunoglobulin (IVIG), is now approved for both acute and maintenance treatment of CIDP in Japan.
Global IVIg Market – Segments
For ease of understanding, the market is segmented into three key dynamics: -
By Types : IgA, (IgA1 & A2), IgD, IgE, IgG, and IgM.
By Applications : Chronic Inflammatory Demyelinating, Hypogammaglobulinemia Multifocal Motor Neuropathy, Immunodeficiency Diseases, CVID (common variable immunodeficiency), SCI (severe combined immunodeficiency), Primary Humoral Immunodeficiency, Unknown (idiopathic) Immunodeficiency diseases, Myasthenia Gravis, Guillain-Barre syndrome, MFS (Miller Fisher Syndrome), AMAN (Acute motor axonal neuropathy) and AMSAN (acute motor-sensory axonal neuropathy), Kawasaki disease, and ITP among others.
By Regions : North America, Asia Pacific, Europe, and the Rest-of-the-World.
Get Complete Report Details with Detail Tables and Figures @ https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137
Global Intravenous Immunoglobulin Market – Regional Analysis
The North American region, heading with the presence of a large number of key players and a well-established healthcare sector accounts for the leading market in the global IVIg market.
The US market backed by the high expenditure on healthcare accounts for the largest contributor to the growth of the regional market. Moreover, the increasing prevalence of immunodeficiency disorder and rising demand for treatment measures provide impetus to market growth.
The intravenous immunoglobulin market in the European region accounts for the second-largest market, globally.
The IVIg market in Europe is fostered by the high per capita income and robust healthcare penetration in the region. The strong market growth in countries like Germany & France drives the regional market growth, large scale. Moreover, factors such as the increasing investments in healthcare and the rising number of patients with immune system diseases are helping the market to create a larger revenue pocket.
The Asia Pacific intravenous immunoglobulin market is expected to perceive an exponential growth. Factors such as the vast population and the burgeoning medical treatment market, especially in India & China, drive the growth of the regional market. Vietnam, Thailand, and Malaysia among the other South East Asian countries are projected to contribute significantly to the market growth in the region. With the growing Medical Tourism markets in India & Malaysia, the APAC region will register a significant CAGR during the review period.
#Intravenous Immunoglobulin (IVIG) Market#Intravenous Immunoglobulin (IVIG) Market Size#Intravenous Immunoglobulin (IVIG) Market Share#Intravenous Immunoglobulin (IVIG) Market Growth
0 notes
Text
Intravenous Immunoglobulin (IVIG) Market Dynamic Demand, Growth, Development and Challenges with Forecast 2025
Facto Market Insights (FMI), added a title on “Intravenous Immunoglobulin (IVIG) Market – 2018-2025” to its collection of market research reports. This market research report provides detailed analysis of market drivers, challenges, opportunity analysis, and trends, along with various key insights. In addition to this, the report on global intravenous immunoglobulin (IVIG) market demonstrates the important aspects that are expected to intensify the growth of the global market over the upcoming years. The study also includes the analysis of the market size and forecast for the different segments &geographies covering the impact analysis of ongoing COVID-19 disease situation.
Get Free Sample Report at https://www.factomarketinsights.com/sample/228
The report on global intravenous immunoglobulin market covers the key market growth indicators, covering the value and supply chain analysis, year-on-year (Y-o-Y) growth and compounded annual growth rate (CAGR), in the Facto Market Insights (FMI) research report along with top macroeconomic indicators. The study is way beneficial for the investors, manufacturers, suppliers, stakeholders, and distributors, because it can help them to understand the strategies of the market and also, they can withdraw information &statistics presented in market research report.
Impact Analysis of Coronavirus Disease (COVID-19)
The research report covers the impact analysis of COVID-19 pandemic on the global intravenous immunoglobulin market, covering information about each region & countries in order to identify the issues raised by the pandemic over various industries. The outbreak of coronavirus or COVID-19 (formerly 2020-nCoV) was noted in December 2019, which has been imposed as a medical emergency across the globe. More than 213 countries and territories have reported cases of coronavirus till date. On 11th March 2020, the World Health Organization (WHO) declared the COVID-19 a pandemic officially. Countries including U.S., India, Italy, Germany, Spain, France, Brazil, and such other countries have a large number of COVID-19 patients, due to which the countries went under lockdown conditions in the past. Thus, with the ongoing situation of lockdown, many industries have been adversely impacted, and it is expected that the economy of such nations are going to suffer a massive loss over the upcoming years, and also the global economy is anticipated to slip into a recession, which is considered to hamper the growth of the overall market.
For Full Report with TOC Visit at https://www.factomarketinsights.com/report/228/intravenous-immunoglobulin-ivig-market-amr
Segment Information
The market for global intravenous immunoglobulin market is segmented as type, application and region.
By Application
Hypogammaglobulinemia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Primary Immunodeficiency Disease Myasthenia Gravis Multifocal Motor Neuropathy Idiopathic Thrombocytopenic Purpura (ITP) Inflammatory Myopathies Specific Antibody Deficiency Guillain Barre Syndrome Others
By Type
IgG IgA IgM IgE IgD
Regional Representation
The market for intravenous immunoglobulin is segregated on the basis of regional basis into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The breakdown of the region into countries is covered in the study. The study also includes the estimations about market growth at the regional and country levels. Further, the regions are fragmented into the country and regional groupings:
- North America (U.S. & Canada)
- Europe (Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East & Africa (GCC, North Africa, South Africa and Rest of Middle East & Africa)
Competitive Landscape:
The report profiles various major & prominent key market players in the global intravenous immunoglobulin market including Baxter international Inc., CSL Ltd., Grifols, Octapharma AG, Kedrion Biopharma Inc., LFB Group, Biotest AG and other key players.
For any Inquiry before buying this report visit at https://www.factomarketinsights.com/enquiry/228
About Us:
Facto Market Insights is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends.
Our in-house research experts have a wealth of knowledge in their respective domains. With Facto Market Research, you always have the choice of getting customized report free of cost (upto 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.
Our clients list includes various Fortune 500 companies and leading advisory firms.
Contact Us:
Facto Market Insights
90 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email:[email protected]
Website: www.factomarketinsights.com
0 notes
Text
Intravenou Immunoglobulin (IVIG) Market Growth, Demand and Analysis 2027
The research report on the global Intravenous Immunoglobulin (IVIG) market provides a comprehensive outlook of the equipment and technological devices employed in the manufacturing of the Intravenous Immunoglobulin (IVIG) market products. From industry chain analysis to cost structure analysis, the report examines various factors of the industry, including production and end-use segments of the Intravenous Immunoglobulin (IVIG) market. The current trends in the pharmaceutical industry have been highlighted in the report to evaluate their influence on the overall output of the Intravenous Immunoglobulin (IVIG) market.
Here, you can avail sample PDF pages and 30 mins free consultation: https://www.reportsanddata.com/sample-enquiry-form/1442
The Intravenous Immunoglobulin (IVIG) industry has witnessed a stable growth rate in the past decade and is expected to continue on the same path in the forthcoming decades. Therefore, it is crucial to recognize all investment opportunities, potential market threats, restraining factors, challenges, market dynamics, and technological development to intensify footholds in the Intravenous Immunoglobulin (IVIG) sector. This report has evaluated all the above mentioned aspects to present a detailed assessment to the reader to assist them in achieving the desired growth in their businesses.
Companies considered and profiled in this market study:
Kemira OYJ (Finland), Dow Chemical Company (US), ArrMaz Products, L.P. (US), AkzoNobel N.V. (Netherlands), BASF SE (Germany), Clariant International Limited (Switzerland), Cytec Industries Inc. (US), HuntsOrica Ltd. (Australia), man International LLC (US), SNF Floreger (France) and others
Type Outlook (Revenue, USD Billion; 2016-2026)
· IgG
· IgA
· IgM
· IgE
· IgD
Application Outlook (Revenue, USD Billion; 2016-2026)
· Hypogammaglobulinemia
· Immunodeficiency Diseases
· Congenital AIDS
· Chronic Inflammatory Demyelinating Polyneuropathy
· Myasthenia Gravis
· Multifocal Motor Neuropathy
· ITP
· Guillain-Barre syndrome
· Kawasaki Diseases
· Others
Avail this report at Attractive Discount rates! Click here to know more @ https://www.reportsanddata.com/discount-enquiry-form/1442
End Users Outlook (Revenue, USD Billion; 2016-2026)
· Hospitals
· Clinics
· Homecare
· Others
Distribution Channel Outlook (Revenue, USD Billion; 2016-2026)
· Hospital Pharmacy
· Specialty Pharmacy
Market Segment by Regions, regional analysis covers:
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, and Italy)
Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
South America (Brazil, Argentina, and Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)
Table of Contents:
Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global Intravenous Immunoglobulin (IVIG) market, duration considered, and objectives of the research. Additionally, it segments the market on the basis of product type and application.
Executive Summary: It offers a summary of other key studies, annual growth rate, competitive landscape, driving factors, market trends and issues, and macroscopic indicators.
Production by Region: Here, the report delivers information related to import and export, production, revenue, and key players of all regional markets inspected in the report.
Profile of Manufacturers: Each firm profiled in this segment is investigated by means of SWOT analysis, available products, global production, value, capacity, and other crucial factors.
Highlights the following key factors:
1) Business description-Detailed description of a firm’s operations and business segments.
2) Corporate strategy – Analyst’s summarization of the company’s business strategy.
3) SWOT Analysis – A detailed analysis of the company’s strengths, weaknesses, opportunities, and challenges.
4) Company history – A company’s evolution, highlighting its key events through the years.
5) Major products and services – A list of flagship products, services, and brands of the company.
6) Key competitors – A list of key competitors of the company.
7) Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
8) Detailed financial ratios for the past five years – The latest financial ratios derived from annual financial statements released by the company in the last five years.
The growth of this market across the globe is dependent on multiple factors; including consumer base of several Intravenous Immunoglobulin (IVIG) products, inorganic growth models adopted by companies, price volatility of feedstocks, and product innovation, along with their economic prospects in both producer and consumer nations.
Access the Entire Report packed with TOC, Tables and Figures and Outline of Prominent Companies @ https://www.reportsanddata.com/report-detail/intravenous-immunoglobulin-market
Overall, this report provides a clear view of every vital factor of the market without the need to refer to any other research reports or data sources. Our report will equip you with all the strategically vital facts about the past, present, and future of the market.
0 notes
Text
Intravenous Immunoglobulin (IVIg) market Overview 2019 By Manufactures and Product scope
Intravenous Immunoglobulin (IVIg), a compound comprising of immune proteins (globulins) is administered into the bloodstream to treat patients with inefficient or damaged immune systems. IVIg provides the required antibodies by the human body to fight out the immune deficiency, and the ensuing infectious attacks.
Immunodeficiency disorder could be a hereditary issue (Primary disorders), or caused due to the exposure to infections, mainly through bodily fluids, along with the cancer drugs and chemotherapy, aging is one of the key risk factors too that could put someone at higher risk of a damaged immune system.
People nowadays are increasingly adopting heady & unhealthy lifestyles which mirror the prevalence of damaged immune system. Factors such as immense stress, lack of good quality sleep, inadequate & improper diet and sedentary lifestyle are fuelling the prevalence of immunodeficiency disorder and therefore, predominantly driving the growth of the market.
Considering the kind of the growth the market perceives currently; Market Research Future (MRFR) has recently published a study report giving out the complete market forecast up to 2023. In its analysis, MRFR asserts that the global intravenous immunoglobulin market growing further will reach USD 8337.2 MN by 2023, registering approximately 5.9% CAGR from 2017 to 2023.
The augmenting demand for alternate immunoglobulin replacement therapies, increasing R&D funding, rapidly developing healthcare infrastructure and increasing healthcare expenditures are major driving forces for the market growth. Technological advancements transpired in medical science, are fostering the growth of the market exponentially, bringing up new treatment procedures, & medications in the field of IVIg.
Additionally, factors such as growing population and geriatric populace worldwide are fostering market growth. Rapidly developing economy worldwide is providing impetus to the market growth, enabling access to the quality life & improved healthcare. Substantial investments made in the development of IVIg, by the key market players are paying off well, driving the growth of the market.
On the flip side, factors such as low awareness among people about the availability of treatment, the high cost of IVIg management along with the skepticism towards the advancement & efficacies of these treatments among the patients are likely to impede the growth of the Intravenous Immunoglobulin market.
Global Intravenous Immunoglobulin Market – Competitive Landscape
Fiercely competitive, the global IVIg market appears to be fragmented due to the presence of several large and small players. These players acquire small yet promising companies to expand their reach in the emerging markets, focusing on improving their market performance. The acquisition of local manufactures by multinational companies makes the market structure look dynamic. Strategies such as product innovations and technologies are creating strong investment opportunities for the players.
Major Players:
Key players leading the global IVIg market include Baxter (US), BDI Pharma (US), Abeona Therapeutics (US), China Biologic Products, Inc. (China), Grifols Inc. (Spain), Biotest AG. (Germany), CSL Behring (US), Octapharma (Switzerland), Kedrion S.p.A (US), and Shire (Republic of Ireland) among others.
Industry, Innovation & Related News
March 28, 2019 --- CSL Behring (the US), a leading global biotherapeutics and biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products announced the receiving of an approval from Japan's Ministry of Health, Labour and Welfare has for two of its immunoglobulin therapies - named Hizentra and Privigen for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
Out of these, Hizentra which was previously approved for the treatment of primary immunodeficiency (PI) is now Japan's first and only subcutaneous immunoglobulin (SCIG) treatment approved for maintenance therapy to treat CIDP. Privigen, an intravenous immunoglobulin (IVIG), is now approved for both acute and maintenance treatment of CIDP in Japan.
Intravenous Immunoglobulin (IVIg) Market information, by type (IgA, IgD, IgE, IgG, IgM), by Appliaction (Chronic inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia, Multifocal Motor Neuropathy, Immunodeficiency diseases, Primary Humoral Immunodeficiency, Myasthenia Gravis, Guillain-Barre syndrome, Kawasaki disease, ITP, and others) - Forecast to 2023: https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137
0 notes
Text
Television Broadcasting Services Market 2025: Emergence of Advanced Technologies and Global Industry Analysis
Shift to Consumer-driven Model Builds Platform for Growth
The global television broadcasting services market is foreseen to gather pace in its growth with advertisement regarded as a leading revenue source and rising demand for HD content. The shift in trend from provider-driven to consumer-driven observed in the television market could bode well for the rise of broadcasting services. Increasing consumer expectations could be met with technological advancement in the manufacturing of devices and rising quality standards.With swelling consumer preference for high-quality content, demand for top-end over-the-top television (OTT) services such as HBO Go is expected to improve in the near future. In 2017, ownership of HD televisions touched 85.0%, according to the finding mentioned in the Ericsson Mobility Report 2017.
For more info, Get Free PDF at: https://www.researchmoz.us/enquiry.php?type=S&repid=1358700
Global Therapeutic Plasma Exchange Market: Scope and Methodology
This report analyzes the current and future prospects of the global therapeutic plasma exchange market. The report comprises a comprehensive executive summary, including a market snapshot that provides overall information of various segments. The report is a combination of primary and secondary research. Primary research formed the bulk of the research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2016 to 2026, considering the macro and micro environmental factors. Growth rates for each segment within the global therapeutic plasma exchange market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the overview section. The report also provides insights into the key trends of the therapeutic plasma exchange market such as rise in prevalence of autoimmune diseases, cost advantage over IVIG treatment, and improvement in health care infrastructure in emerging economies. Key market indicators influencing the global therapeutic plasma exchange market, including cost constraints and regulatory landscape, have been taken into consideration. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global therapeutic plasma exchange market.
Market revenue in terms of US$ Mn for the period between 2016 and 2026 along with the compound annual growth rate (CAGR %) from 2018 to 2026 are provided for all the segments, considering 2017 as the base year. The year-on-year growth of the global therapeutic plasma exchange market for each segment is also provided. Additionally, market-related factors such as favorable reimbursement scenario, expanding applications in chronic diseases, side effects associated with plasmapheresis and historical year-on-year growth have been taken into consideration while estimating the market size.
Place an Enquiry to Our Industry Expert @ https://www.researchmoz.us/enquiry.php?type=E&repid=1358700
Global Therapeutic Plasma Exchange Market: Segmentation
Based on disease indication, the global therapeutic plasma exchange market has been segmented into neurological disorders, renal disorders, hematology disorders, metabolic disorders, and others. The neurological disorders segment has been classified into chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, multiple sclerosis, neuromyelitis optica, and Guillain-Barré syndrome. The renal disorders segment has been categorized into post-renal transplant rejection, anti-glomerular basement membrane (anti-GMB) disease, and Wegener’s granulomatosis. The hematology disorders segment has been divided into thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, cryoglobulinemia, multiple myeloma, metabolic disorders, familial hypercholesterolaemia (homozygous), and fulminant Wilson disease. In terms of end-user, the market has been classified into hospitals, specialty clinics, and ambulatory surgical centers. The hospitals segment is expected to dominate the market during the forecast period.
In terms of region, the global therapeutic plasma exchange market has been segment into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been divided into major countries/sub-regions in each of the regions. These include the U.S., Canada, the U.K., Germany, Russia, France, Italy, Spain, China, Australia, Japan, India, Brazil, GCC Countries, South Africa, and Mexico.
Global Therapeutic Plasma Exchange Market: Competitive Landscape
The report also profiles major players in the global therapeutic plasma exchange market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun Melsungen AG, Fresenius Kabi AG, Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Hemacare Corporation, and Medica S.p.A.
About ResearchMoz ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact: ResearchMoz Mr. Nachiket Ghumare, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Website: https://www.researchmoz.us Email: [email protected] Blog: https://blogreportstudy.blogspot.com/
0 notes
Text
Therapeutic Plasma Exchange Market to Become Worth US$ 2,015.93 Mn by 2026
Global Therapeutic Plasma Exchange Market: Scope and Methodology
This report analyzes the current and future prospects of the global therapeutic plasma exchange market. The report comprises a comprehensive executive summary, including a market snapshot that provides overall information of various segments. The report is a combination of primary and secondary research. Primary research formed the bulk of the research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2016 to 2026, considering the macro and micro environmental factors. Growth rates for each segment within the global therapeutic plasma exchange market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
Obtain Report Details @
https://www.transparencymarketresearch.com/therapeutic-plasma-exchange-market.html
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the overview section. The report also provides insights into the key trends of the therapeutic plasma exchange market such as rise in prevalence of autoimmune diseases, cost advantage over IVIG treatment, and improvement in health care infrastructure in emerging economies. Key market indicators influencing the global therapeutic plasma exchange market, including cost constraints and regulatory landscape, have been taken into consideration. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global therapeutic plasma exchange market.
Market revenue in terms of US$ Mn for the period between 2016 and 2026 along with the compound annual growth rate (CAGR %) from 2018 to 2026 are provided for all the segments, considering 2017 as the base year. The year-on-year growth of the global therapeutic plasma exchange market for each segment is also provided. Additionally, market-related factors such as favorable reimbursement scenario, expanding applications in chronic diseases, side effects associated with plasmapheresis and historical year-on-year growth have been taken into consideration while estimating the market size.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14072
Global Therapeutic Plasma Exchange Market: Segmentation
Based on disease indication, the global therapeutic plasma exchange market has been segmented into neurological disorders, renal disorders, hematology disorders, metabolic disorders, and others. The neurological disorders segment has been classified into chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, multiple sclerosis, neuromyelitis optica, and Guillain-Barré syndrome. The renal disorders segment has been categorized into post-renal transplant rejection, anti-glomerular basement membrane (anti-GMB) disease, and Wegener’s granulomatosis. The hematology disorders segment has been divided into thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, cryoglobulinemia, multiple myeloma, metabolic disorders, familial hypercholesterolaemia (homozygous), and fulminant Wilson disease. In terms of end-user, the market has been classified into hospitals, specialty clinics, and ambulatory surgical centers. The hospitals segment is expected to dominate the market during the forecast period.
Request Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14072
In terms of region, the global therapeutic plasma exchange market has been segment into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been divided into major countries/sub-regions in each of the regions. These include the U.S., Canada, the U.K., Germany, Russia, France, Italy, Spain, China, Australia, Japan, India, Brazil, GCC Countries, South Africa, and Mexico.
0 notes
Text
Global Intravenous Immunoglobulin (IVIG) Market is Bost at a CAGR 7.5 % During 2018-2025
KD Market Insights has published a research report about Global Intravenous Immunoglobulin (IVIG) market that envisions boost for this market with 7.5 % CAGR (Compound Annual Growth Rate) for this market between 2018 and 2023. In terms of value, the market that is worth the USD $8,995 Million in 2017 is expected to be worth the USD $15,964 Million in 2025. The market research report demonstrates market dynamics which includes growth drivers, restraining factors and opportunities and trends spearheading current nature and future status of this market. In addition to this, the report includes market size, Y-O-Y growth analysis and structure of the overall industry based on a unique combination of industry research, fieldwork, market sizing analysis, and our in-house expertise. Our general approach is to target several individuals with specific questions that we believed would satisfy our research objective. Further, to speed up the data collection process, we employed an online survey, delivered via email. Also, the research team analysed the results to identify potential opportunities and risks for the market. Request for Sample @ https://www.kdmarketinsights.com/sample/3385 Segmentation By Application - Hypogammaglobulinemia - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Primary Immunodeficiency Disease - Myasthenia Gravis - Multifocal Motor Neuropathy - Idiopathic Thrombocytopenic Purpura (ITP) - Inflammatory Myopathies - Specific Antibody Deficiency - Guillain–Barre Syndrome - Others By Type - IgG - IgA - IgM - IgE - IgD Regional Outlook. The report analyses the market by geographies i.e. North America, Europe, Asia Pacific, Latin America & Middle East & Africa. Further, the geographies are fragmented into the country and regional groupings: - North America (U.S. & Canada) - Europe (Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe) - Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific) - Latin America (Brazil, Mexico, Argentina and Rest of Latin America) - Middle East & Africa (GCC, North Africa, South Africa and Rest of Middle East & Africa) Competitive Landscape: The competitive landscape analysis provides detailed strategic analysis of the company’s business and performance such as financial information, revenue breakup by segment and by geography, SWOT Analysis, key facts, company overview, business strategy, key product offerings, marketing and distribution strategies, new product development, recent news (acquisition, expansion, technology development, research & development and other market activities). The study also provides company’s positioning and market share in Intravenous Immunoglobulin (IVIG) market. Competitive Landscape: - Baxter international Inc. - CSL Ltd. - Grifols, S.A. - Octapharma AG - Kedrion Biopharma Inc. - LFB Group - Biotest AG - China Biologics Products, Inc. - Takeda Pharmaceuticals - Bayer AG Browse Full Report With TOC@ https://www.kdmarketinsights.com/product/intravenous-immunoglobulin-market-amr Table of Content CHAPTER 1: INTRODUCTION 1.1. Report description 1.2. Key benefits for stakeholders 1.3. Key market segments 1.4. Research methodology 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools & models CHAPTER 2: EXECUTIVE SUMMARY 2.1. CXO perspective CHAPTER 3: MARKET OVERVIEW 3.1. Market definition and scope 3.2. Overview of Immunoglobulin 3.2.1. Patented products 3.2.2. Epidemiology and economic burden of chronic conditions 3.3. Key findings 3.3.1. Top Investment Pockets 3.4. Porters five forces analysis 3.5. Value chain analysis 3.5.1. Primary activities 3.5.2. Support activities 3.6. Market share analysis, 2017 3.7. Product scenario in intravenous immunoglobulin market 3.8. Government regulations and reimbursements 3.8.1. U.S. 3.8.2. Europe 3.8.3. France 3.8.4. Germany 3.8.5. Italy 3.8.6. China 3.8.7. Japan 3.8.8. India 3.9. Indications for immunoglobulin 3.9.1. U.S. FDA indications 3.9.2. EMA 3.10. Component analysis of immunoglobulin G (IgG) 3.10.1. IgG1 3.10.2. IgG2 3.10.3. IgG3 3.10.4. IgG4 3.11. Market dynamics 3.11.1. Drivers 3.11.1.1. Rise in prevalence of immunodeficiency diseases 3.11.1.2. Increase in adoption of immunoglobulin treatment 3.11.1.3. Growth in incidence of bleeding disorders 3.11.2. Restraints 3.11.2.1. Stringent government regulations 3.11.2.2. High cost of therapy 3.11.3. Opportunities 3.11.3.1. Opportunities in emerging economies 3.11.3.2. Development of cost-effective therapeutics through large-scale production CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION 4.1. Overview 4.1.1. Market size and forecast 4.2. Hypogammaglobulinemia 4.2.1. Market size and forecast 4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP) 4.3.1. Market size and forecast 4.4. Primary immunodeficiency diseases 4.4.1. Market size and forecast 4.5. Myasthenia Gravis 4.5.1. Market size and forecast 4.6. Multifocal motor neuropathy 4.6.1. Market size and forecast 4.7. Idiopathic thrombocytopenic purpura (ITP) 4.7.1. Market size and forecast 4.8. Inflammatory myopathies 4.8.1. Market size and forecast 4.9. Specific antibody deficiency 4.9.1. Market size and forecast 4.10. Guillain-Barre syndrome 4.10.1. Market size and forecast 4.11. Others 4.11.1. Market size and forecast CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT 5.1. Overview 5.1.1. IGG 5.1.1.1. Key market trends 5.1.2. Clinical interpretations 5.1.3. IGA 5.1.3.1. Key Market Trends 5.1.4. Clinical interpretation 5.1.5. IGM 5.1.5.1. Key Market Trends 5.1.6. Clinical interpretation 5.1.7. IGE 5.1.7.1. Key Market Trend 5.1.8. Clinical interpretation 5.1.9. IGD 5.1.9.1. Key Market Trends 5.1.10. Clinical interpretation CHAPTER 6: INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION 6.1. Overview 6.1.1. Market size and forecast 6.2. North America 6.2.1. Key trends and opportunities 6.2.2. North America market size & forecast, by application 6.2.3. North America market size & forecast, by country 6.2.3.1. U.S. market size & forecast 6.2.3.2. Canada market size & forecast 6.2.3.3. Mexico market size & forecast Continue…. Check for Discount @ https://www.kdmarketinsights.com/discount/3385 About Us: KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market. Contact Us: KD Market Insights 150 State Street, Albany, New York, USA 12207 +1 (518) 300-1215 Email: [email protected] Website: www.kdmarketinsights.com
#Intravenous Immunoglobulin Market#Intravenous Immunoglobulin Market size#Intravenous Immunoglobulin Market share#Intravenous Immunoglobulin Market news
0 notes
Text
Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
This report on the global intravenous immunoglobulin (IVIG) market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global intravenous immunoglobulin (IVIG) market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the intravenous immunoglobulin (IVIG) market such as shift from intravenous to subcutaneous infusion of immunoglobulin. The key market indicators influencing global intravenous immunoglobulin (IVIG) market taken into consideration include prevalence of immunological disorders, global blood and plasma yield and geriatric population. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global intravenous immunoglobulin (IVIG) market. The report also highlights key events of the global intravenous immunoglobulin industry. A value chain analysis along with list of major players, hospitals and distributors is also included in the report.
This 155 page report gives readers a comprehensive overview of the Intravenous Immunoglobulin Market. Browse through 18 data tables and 56 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/intravenous-immunoglobulin-market.html
Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. The year on year growth of global intravenous immunoglobulin (IVIG) market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and growing number of acute and chronic patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.
Based on indication, the global intravenous immunoglobulin (IVIG) market has been segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. Based on end-user, the market has been segmented into hospitals, clinics, and home care. Hospitals segment is expected to remain dominant during the forecast period. However, home care segment is expected to grow at a higher CAGR than others.
Get accurate market forecast and analysis on the Intravenous Immunoglobulin Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930
Geographically, the global intravenous immunoglobulin (IVIG) market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.
The report also profiles major players in the intravenous immunoglobulin (IVIG) market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the intravenous immunoglobulin (IVIG) market is provided in the report. The report also includes a competition matrix that provides insights into recent developments and activities done by the major market players. Key companies profiled in the report include Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V.
Contact us:
Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com/
0 notes
Text
Global Intravenous Immunoglobulin (IVIG) Market: Rising Patient Pool of Neurological Disorders to Boost Global Consumption of IVIG Products, observes TMR
The global intravenous immunoglobulin (IVIG) market is largely consolidated, with top four players: Grifols S.A., CSL Behring LLC, Baxalta Incorporated, and Octapharma AG, accounting for over 70% of the overall market in 2015. Grifols S.A. accounted for the dominant share of 23.0%, chiefly on account of the company’s strong geographic penetration.
Oligopoly in the market has led to intense competition among top players and has compelled companies to take course of strategic mergers and acquisitions and geographic expansions. Point in case is the CSL Behring LLC’s geographic expansion by opening operations in Russia in December 2015. The company stated that the expansion was driven by large unmet need of quality biotherapeutics and blood plasma products in the country.
Browse Global Strategic Business Report:
http://www.transparencymarketresearch.com/intravenous-immunoglobulin-market.html
Transparency Market Research estimates that the global intravenous immunoglobulin (IVIG) market, which was valued at US$7.23 bn in 2015, is projected to expand at a CAGR of 8.5% from 2016 to 2024 and reach US$14.92 bn in 2024. In terms of end users, the hospitals segment is presently leading, accounting for a more than 62% of the overall market in 2015. The segment is, however, expected to lose prominence to the home care segment and reflect a loss in its overall share by 2024. In terms of geography, North America, which presently accounts for over 45% of the global market, is expected to retain dominance by 2024 as well.
Rising Prevalence of Neurological Diseases to Boost Global Demand for IVIG Products
The rapidly rising prevalence of a variety of hematological and neurological disorders such as alloimmune thrombocytopenia, idiopathic thrombocytopenic purpura (ITP), and myasthenia gravis is the chief factor driving the intravenous immunoglobulin (IVIG) market. For instance, the occurrence of myasthenia gravis in the U.S. has been assessed at 14 to 20 cases out of 100,000 people, which comes to around 36,000 to 60,000 cases in the country. This neuromuscular transmission has a high probability of remaining undiagnosed and thus the prevalence of this disease is actually much higher. Over 40% of the world’s IVIG products are used to treat neurological diseases, thus the rising prevalence of neurological disorders is a highly significant factor of growth for the global IVIG market.
Moreover, the mounting global population of geriatrics, which is more vulnerable to diseases due to poor immunity, is also a key factor driving the IVIG market. According to the WHO, the global geriatric population is expected to increase from 524 mn in 2010 to 1.5 bn by 2050. This is anticipated to drive the increased demand for better immunological treatments, which in turn would provide opportunities for companies operating in the global intravenous immunoglobulin market. The steady rise in the use of intravenous immunoglobulin for the treatment of off-label indications a significant rise in the blood plasma yield across the globe are also likely to drive the intravenous immunoglobulin (IVIG) products market.
High Cost of Treatment and Potential Side Effects to Hamper Market Growth
One of the key challenges that could hamper the overall development of the global IVIG market is the comparatively much higher cost of plasma collection and manufacturing processes as compared to conventional pharmaceutical manufacturing and processing products. Moreover, immunoglobulin products being derivatives of blood, they require highly sophisticated methods and equipment for collection, purification, and storage. This scenario adds to the overall cost and complexity of IVIG products and therapies.
Intravenous immunoglobulin (IVIG) preparations also have several related side effects, which could lead to serious health problems in some patients. Owing to this, patients are sometimes discouraged from continuing IVIG therapies. Side effects associated with the use of IVIG also sometimes encourage clinicians to opt for alternate therapies. This factor is likely to restrain the overall development of the intravenous immunoglobulin (IVIG) market in the next few years.
This review of the market is based on a recent market research report published by Transparency Market Research, titled “Intravenous Immunoglobulin (IVIG) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”
For this study, the global IVIG market is segmented as follows:
Global Intravenous immunoglobulin (IVIG) Market, by Indication
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Humoral Immunodeficiency
Idiopathic Thrombocytopenic Purpura (ITP)
Guillain-Barre Syndrome
Myasthenia Gravis
Multifocal Motor Neuropathy (MMN)
Kawasaki Disease
Hypogammaglobulinemia
Chronic Lymphocytic Leukemia
Others
Global Intravenous immunoglobulin (IVIG) Market, by End-user
Hospitals
Clinics
Home Care
Global Intravenous immunoglobulin (IVIG) Market, by Geography
North America
U.S.
Canada
Europe
U.K
Germany
France
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
Australia
India
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
South Africa
Saudi Arabia
Rest of Middle East & Africa
Download Exclusive Brochure of This Report :
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com
0 notes
Text
Intravenous Immunoglobulin (IVIG) Market Perceptions Targeting Industrial Expansion Studied during the Forecast Period, 2018-2025
The global intravenous immunoglobulin (IGIV) market was valued at $8,995 million in 2017and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Immunoglobulins (IGs), also referred to as antibodies, are glycoproteins produced by the blood plasma in response to foreign bodies or antigens. They are highly complex entities and are specific in their action. These immunoglobulins are obtained from blood through the process of fractionation and are purified for use in therapeutic and nontherapeutic areas.
Request for Sample Report @ https://www.factomarketinsights.com/sample/228
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia, & others and rise in adoption of immunoglobulin therapies for the treatment of various autoimmune disorders majorly drive the growth of the IVIG market. Furthermore, increase in approval of IVIG drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and other government agencies is expected to accelerate the growth of the IVIG industry. However, stringent government regulations toward the vigorous use of immunoglobulins, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin intravenously are anticipated to hamper the market growth. On the contrary, significant investment in healthcare sector is expected to provide lucrative opportunities for the market growth in the near future.
The global intravenous immunoglobulin (IVIG) market is characterized based on application, type, and region. By application, the market is segmented into hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, Guillain–Barre syndrome, and others. Depending on type, it is classified into IgG, IgA, IgM, IgE, and IgD. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Click to Get Complete Research report with TOC @ https://www.factomarketinsights.com/report/228/intravenous-immunoglobulin-ivig-market-amr
Key Benefits for Intravenous Immunoglobulin Market:
The report provides an in-depth analysis of the intravenous immunoglobulin market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in this study.
The report provides a detailed quantitative analysis of the industry from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the key segments of the industry helps to understand the trends in the intravenous immunoglobulin market globally.
Key players and their strategies are provided to understand the competitive outlook of the industry.
Intravenous Immunoglobulin Key Market Segments:
By Application
Hypogammaglobulinemia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Primary Immunodeficiency Disease Myasthenia Gravis Multifocal Motor Neuropathy Idiopathic Thrombocytopenic Purpura (ITP) Inflammatory Myopathies Specific Antibody Deficiency Guillain–Barre Syndrome Others
By Type
IgG IgA IgM IgE IgD
Get Sample Report for Detailed Insights @ https://www.factomarketinsights.com/sample/228
By Region
North America U.S. Canada Mexico Europe UK France Germany Italy France Austria Russia Rest of Europe Asia-Pacific Japan China India Australia Rest of Asia-Pacific LAMEA Brazil Argentina Turkey Saudi Arabia Rest of LAMEA
Key Players Profiled
Baxter international Inc. CSL Ltd. Grifols, S.A. Octapharma AG Kedrion Biopharma Inc. LFB Group Biotest AG China Biologics Products, Inc. Takeda Pharmaceuticals Bayer AG
0 notes
Text
Intravenous Immunoglobulin (IVIG) Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024
The global intravenous immunoglobulin (IVIG) market is largely consolidated, with top four players: Grifols S.A., CSL Behring LLC, Baxalta Incorporated, and Octapharma AG, accounting for over 70% of the overall market in 2015. Grifols S.A. accounted for the dominant share of 23.0%, chiefly on account of the company’s strong geographic penetration.
Oligopoly in the market has led to intense competition among top players and has compelled companies to take course of strategic mergers and acquisitions and geographic expansions. Point in case is the CSL Behring LLC’s geographic expansion by opening operations in Russia in December 2015. The company stated that the expansion was driven by large unmet need of quality biotherapeutics and blood plasma products in the country.
Transparency Market Research estimates that the global intravenous immunoglobulin (IVIG) market, which was valued at US$7.23 bn in 2015, is projected to expand at a CAGR of 8.5% from 2016 to 2024 and reach US$14.92 bn in 2024. In terms of end users, the hospitals segment is presently leading, accounting for a more than 62% of the overall market in 2015. The segment is, however, expected to lose prominence to the home care segment and reflect a loss in its overall share by 2024. In terms of geography, North America, which presently accounts for over 45% of the global market, is expected to retain dominance by 2024 as well.
Browse Global Strategic Business Report: http://www.transparencymarketresearch.com/intravenous-immunoglobulin-market.html
Rising Prevalence of Neurological Diseases to Boost Global Demand for IVIG Products
The rapidly rising prevalence of a variety of hematological and neurological disorders such as alloimmune thrombocytopenia, idiopathic thrombocytopenic purpura (ITP), and myasthenia gravis is the chief factor driving the intravenous immunoglobulin (IVIG) market. For instance, the occurrence of myasthenia gravis in the U.S. has been assessed at 14 to 20 cases out of 100,000 people, which comes to around 36,000 to 60,000 cases in the country. This neuromuscular transmission has a high probability of remaining undiagnosed and thus the prevalence of this disease is actually much higher. Over 40% of the world’s IVIG products are used to treat neurological diseases, thus the rising prevalence of neurological disorders is a highly significant factor of growth for the global IVIG market.
Moreover, the mounting global population of geriatrics, which is more vulnerable to diseases due to poor immunity, is also a key factor driving the IVIG market. According to the WHO, the global geriatric population is expected to increase from 524 mn in 2010 to 1.5 bn by 2050. This is anticipated to drive the increased demand for better immunological treatments, which in turn would provide opportunities for companies operating in the global intravenous immunoglobulin market. The steady rise in the use of intravenous immunoglobulin for the treatment of off-label indications a significant rise in the blood plasma yield across the globe are also likely to drive the intravenous immunoglobulin (IVIG) products market.
High Cost of Treatment and Potential Side Effects to Hamper Market Growth
One of the key challenges that could hamper the overall development of the global IVIG market is the comparatively much higher cost of plasma collection and manufacturing processes as compared to conventional pharmaceutical manufacturing and processing products. Moreover, immunoglobulin products being derivatives of blood, they require highly sophisticated methods and equipment for collection, purification, and storage. This scenario adds to the overall cost and complexity of IVIG products and therapies.
Intravenous immunoglobulin (IVIG) preparations also have several related side effects, which could lead to serious health problems in some patients. Owing to this, patients are sometimes discouraged from continuing IVIG therapies. Side effects associated with the use of IVIG also sometimes encourage clinicians to opt for alternate therapies. This factor is likely to restrain the overall development of the intravenous immunoglobulin (IVIG) market in the next few years.
This review of the market is based on a recent market research report published by Transparency Market Research, titled “Intravenous Immunoglobulin (IVIG) Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”
Download Free exclusive Sample of this report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930
For this study, the global IVIG market is segmented as follows:
Global Intravenous immunoglobulin (IVIG) Market, by Indication
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Humoral Immunodeficiency
Idiopathic Thrombocytopenic Purpura (ITP)
Guillain-Barre Syndrome
Myasthenia Gravis
Multifocal Motor Neuropathy (MMN)
Kawasaki Disease
Hypogammaglobulinemia
Chronic Lymphocytic Leukemia
Others
Global Intravenous immunoglobulin (IVIG) Market, by End-user
Hospitals
Clinics
Home Care
Global Intravenous immunoglobulin (IVIG) Market, by Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
U.S.
Canada
U.K
Germany
France
Spain
Italy
Rest of Europe
China
Japan
Australia
India
Rest of Asia Pacific
Brazil
Mexico
Rest of Latin America
South Africa
Saudi Arabia
Rest of Middle East & Africa
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Contact
Mr.Sudip S 90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com
0 notes
Text
Intravenous Immunoglobulin (IVIG) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
The global intravenous immunoglobulin (IVIG) market is largely consolidated, with top four players: Grifols S.A., CSL Behring LLC, Baxalta Incorporated, and Octapharma AG, accounting for over 70% of the overall market in 2015. Grifols S.A. accounted for the dominant share of 23.0%, chiefly on account of the company’s strong geographic penetration.
Oligopoly in the market has led to intense competition among top players and has compelled companies to take course of strategic mergers and acquisitions and geographic expansions. Point in case is the CSL Behring LLC’s geographic expansion by opening operations in Russia in December 2015. The company stated that the expansion was driven by large unmet need of quality biotherapeutics and blood plasma products in the country.
Transparency Market Research estimates that the global intravenous immunoglobulin (IVIG) market, which was valued at US$7.23 bn in 2015, is projected to expand at a CAGR of 8.5% from 2016 to 2024 and reach US$14.92 bn in 2024. In terms of end users, the hospitals segment is presently leading, accounting for a more than 62% of the overall market in 2015. The segment is, however, expected to lose prominence to the home care segment and reflect a loss in its overall share by 2024. In terms of geography, North America, which presently accounts for over 45% of the global market, is expected to retain dominance by 2024 as well.
Rising Prevalence of Neurological Diseases to Boost Global Demand for IVIG Products
The rapidly rising prevalence of a variety of hematological and neurological disorders such as alloimmune thrombocytopenia, idiopathic thrombocytopenic purpura (ITP), and myasthenia gravis is the chief factor driving the intravenous immunoglobulin (IVIG) market. For instance, the occurrence of myasthenia gravis in the U.S. has been assessed at 14 to 20 cases out of 100,000 people, which comes to around 36,000 to 60,000 cases in the country. This neuromuscular transmission has a high probability of remaining undiagnosed and thus the prevalence of this disease is actually much higher. Over 40% of the world’s IVIG products are used to treat neurological diseases, thus the rising prevalence of neurological disorders is a highly significant factor of growth for the global IVIG market.
Moreover, the mounting global population of geriatrics, which is more vulnerable to diseases due to poor immunity, is also a key factor driving the IVIG market. According to the WHO, the global geriatric population is expected to increase from 524 mn in 2010 to 1.5 bn by 2050. This is anticipated to drive the increased demand for better immunological treatments, which in turn would provide opportunities for companies operating in the global intravenous immunoglobulin market. The steady rise in the use of intravenous immunoglobulin for the treatment of off-label indications a significant rise in the blood plasma yield across the globe are also likely to drive the intravenous immunoglobulin (IVIG) products market.
High Cost of Treatment and Potential Side Effects to Hamper Market Growth
One of the key challenges that could hamper the overall development of the global IVIG market is the comparatively much higher cost of plasma collection and manufacturing processes as compared to conventional pharmaceutical manufacturing and processing products. Moreover, immunoglobulin products being derivatives of blood, they require highly sophisticated methods and equipment for collection, purification, and storage. This scenario adds to the overall cost and complexity of IVIG products and therapies.
Intravenous immunoglobulin (IVIG) preparations also have several related side effects, which could lead to serious health problems in some patients. Owing to this, patients are sometimes discouraged from continuing IVIG therapies. Side effects associated with the use of IVIG also sometimes encourage clinicians to opt for alternate therapies. This factor is likely to restrain the overall development of the intravenous immunoglobulin (IVIG) market in the next few years.
This review of the market is based on a recent market research report published by Transparency Market Research, titled “Intravenous Immunoglobulin (IVIG) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”
Download Free exclusive Sample of this report:
http://www.transparencymarketresearch.com/intravenous-immunoglobulin-market.htmlhttp://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930
For this study, the global IVIG market is segmented as follows:
Global Intravenous immunoglobulin (IVIG) Market, by Indication
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Humoral Immunodeficiency
Idiopathic Thrombocytopenic Purpura (ITP)
Guillain-Barre Syndrome
Myasthenia Gravis
Multifocal Motor Neuropathy (MMN)
Kawasaki Disease
Hypogammaglobulinemia
Chronic Lymphocytic Leukemia
Others
Global Intravenous immunoglobulin (IVIG) Market, by End-user
Hospitals
Clinics
Home Care
Global Intravenous immunoglobulin (IVIG) Market, by Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
U.S.
Canada
U.K
Germany
France
Spain
Italy
Rest of Europe
China
Japan
Australia
India
Rest of Asia Pacific
Brazil
Mexico
Rest of Latin America
South Africa
Saudi Arabia
Rest of Middle East & Africa
Browse : Our new press releases
http://www.transparencymarketresearch.com/pressrelease/intravenous-immunoglobulin-market.htm
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Contact
Mr.Sudip S 90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com
0 notes